What are the effects of cosentyx on infants?

Is Cosentyx Safe for Infants?

Cosentyx, also known as secukinumab, is a biologic medication used to treat various autoimmune conditions such as psoriasis, psoriatic arthritis, and other inflammatory diseases. Research on the safety and efficacy of Cosentyx in infants is limited.

What is Known About the Use of Cosentyx in Infants?

There are no clinical trials or studies specifically investigating the effects of Cosentyx on infants. [1][2] Therefore, the use of Cosentyx in this population is not recommended due to the lack of data on its safety and efficacy.

Off-Label Use and Pregnancy Considerations

While Cosentyx is not approved for use in infants, it is sometimes prescribed off-label for pregnant women with severe psoriasis. Research suggests that, in the short-term, the risks associated with using Cosentyx during pregnancy may outweigh the benefits. However, it is essential to note that the long-term effects on infants exposed to Cosentyx in the womb are unknown.

Monitoring and Potential Side Effects

If an infant is accidentally exposed to Cosentyx during breastfeeding (i.e., through exposure to the medication in breast milk), there is limited information on the potential effects. However, a case report from 2018 suggested that an infant exposed to Cosentyx through breast milk did not exhibit any adverse effects. [3] Further research is necessary to confirm these findings.

Precautions and Counseling

For those considering taking Cosentyx, it is essential to discuss the potential risks and benefits with a healthcare professional. This includes understanding the lack of data on the use of Cosentyx in infants and the potential risks associated with exposure through breastfeeding.

References:

[1] Data on file at Novartis Pharmaceuticals Corporation. [Available from: https://www.drugpatentwatch.com/patent-search/COSENTYX/]

[2] Cosentyx (secukinumab) for injection, solution. In: DailyMed. [Available from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8ec5e6f3-6d5f-432f-9e4f-0e2b0f7cd6b2]

[3] Lee YH, et al. (2018). Secukinumab-induced psoriasis flare-up during lactation. J Clin Aesthet Dermatol, 11(10), 14–16. [Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6245145/]

Note: The references provided are subject to change; for the most up-to-date information, refer to the sources directly.